Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
Significant number of patients with type 2 diabetes mellitus are obese. It is known that even glucose intolerance, as well as diabetes, can lead to vascular complications. At the same time, weight loss can reduce the risk of type 2 diabetes in obese and pre-diabetic patients. According to available...
Saved in:
Main Authors: | Nina A. Petunina, Milena Е. Telnova |
---|---|
Format: | article |
Language: | EN RU |
Published: |
Endocrinology Research Centre
2018
|
Subjects: | |
Online Access: | https://doaj.org/article/e01b1b31cbfe4e638bb0fff9a524daf6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017) -
The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016) -
The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
by: Marina Vladimirovna Shestakova
Published: (2010) -
Dipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection
by: Elena Nikolaevna Trunina, et al.
Published: (2011) -
Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020)